Search Patents
  • METHOD OF HUMAN LEUKOCYTE ANTIGEN LOSS OF HETEROZYGOSITY DETECTION IN LIQUID BIOPSIES
    Publication number: 20250069688
    Abstract: Provided herein are methods of determining loss of heterozygosity in human leukocyte antigen in liquid biopsies and applications thereof in cancer treatment.
    Type: Application
    Filed: January 13, 2023
    Publication date: February 27, 2025
    Inventors: Andrew SINKOE, James GULLEY, Christian HINRICHS, Scott Alberto NORBERG, Clint ALLEN, Nisha NAGARSHETH, Xiaolin WU, Ling SU
  • HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST CD22
    Publication number: 20240239864
    Abstract: Disclosed are isolated or purified T cell receptors (TCRs), wherein the TCRs have antigenic specificity for a CD22 amino acid sequence presented by a human leukocyte antigen (HLA) Class I molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
    Type: Application
    Filed: February 16, 2022
    Publication date: July 18, 2024
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Kazusa Ishii, Christian Hinrichs
  • COMBINATION PDL1 AND TGF-BETA BLOCKADE IN PATIENTS WITH HPV+ MALIGNANCIES
    Publication number: 20200062849
    Abstract: The invention provides a method of inhibiting a malignancy associated with human papilloma virus (HPV) comprising administering to a subject an agent that blocks PD-L1 and TGF-beta pathways, thereby inhibiting a malignancy associated with HPV in the subject.
    Type: Application
    Filed: May 8, 2018
    Publication date: February 27, 2020
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Julius Y. Strauss, James L. Gulley, Christian S. Hinrichs
  • TETHERED INTERLEUKIN-15 AND INTERLEUKIN-21
    Publication number: 20210052647
    Abstract: Disclosed are nucleic acids and polypeptides which provide the co-expression of interleukin (IL)-21 and IL-15 by a host cell, each interleukin being bound to the cell membrane by a cell membrane anchor moiety. Also disclosed are related recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, and methods of treating or preventing cancer.
    Type: Application
    Filed: February 7, 2019
    Publication date: February 25, 2021
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Christian S. Hinrichs, Benjamin Y. Jin
  • TETHERED INTERLEUKIN-15 AND INTERLEUKIN-21
    Publication number: 20230355677
    Abstract: Disclosed are nucleic acids and polypeptides which provide the co-expression of interleukin (IL)-21 and IL-15 by a host cell, each interleukin being bound to the cell membrane by a cell membrane anchor moiety. Also disclosed are related recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, and methods of treating or preventing cancer.
    Type: Application
    Filed: May 2, 2023
    Publication date: November 9, 2023
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Servic
    Inventors: Christian S. Hinrichs, Benjamin Y. Jin
  • Combination PDL1 and TGF-beta blockade in patients with HPV+ malignancies
    Patent number: 11440963
    Abstract: The invention provides a method of inhibiting a malignancy associated with human papilloma virus (HPV) comprising administering to a subject an agent that blocks PD-L1 and TGF-beta pathways, thereby inhibiting a malignancy associated with HPV in the subject.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: September 13, 2022
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Julius Y. Strauss, James L. Gulley, Christian S. Hinrichs
  • Tethered interleukin-15 and interleukin-21
    Patent number: 12157762
    Abstract: Disclosed are nucleic acids and polypeptides which provide the co-expression of interleukin (IL)-21 and IL-15 by a host cell, each interleukin being bound to the cell membrane by a cell membrane anchor moiety. Also disclosed are related recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, and methods of treating or preventing cancer.
    Type: Grant
    Filed: May 2, 2023
    Date of Patent: December 3, 2024
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Christian S. Hinrichs, Benjamin Y. Jin
  • ANTI-KK-LC-1 T CELL RECEPTORS
    Publication number: 20190135891
    Abstract: Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for Kita-Kyushu Lung Cancer Antigen 152-60 (KK-LC-152-60). Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
    Type: Application
    Filed: April 17, 2017
    Publication date: May 9, 2019
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Service
    Inventors: Sanja Stevanovic, Christian S. Hinrichs
  • HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST CD20
    Publication number: 20230312672
    Abstract: Disclosed are isolated or purified T cell receptors (TCRs), wherein the TCRs have antigenic specificity for a CD20 amino acid sequence presented by a human leukocyte antigen (HLA) Class I molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
    Type: Application
    Filed: June 23, 2021
    Publication date: October 5, 2023
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Kazusa Ishii, Christian S. Hinrichs
  • Anti-KK-LC-1 T cell receptors
    Patent number: 11352410
    Abstract: Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for Kita-Kyushu Lung Cancer Antigen 152-60 (KK-LC-152-60). Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
    Type: Grant
    Filed: April 17, 2017
    Date of Patent: June 7, 2022
    Assignee: The United States of American, as represented by the Secretary, Department of Health and Human Service
    Inventors: Sanja Stevanovic, Christian S. Hinrichs
  • ENHANCED ANTIGEN REACTIVITY OF IMMUNE CELLS EXPRESSING A MUTANT NON-SIGNALING CD3 ZETA CHAIN
    Publication number: 20240018210
    Abstract: Disclosed is a cell expressing a modified CD3 subunit chain or a cell expressing a modified non-CD3 subunit chain comprising one or more of: (a) at least one Immuno-receptor Tyrosine-based Activation Motif (ITAM) deletion; or (b) at least one exogenous intracellular hematopoietic cell signaling domain; and (c) at least one modified ITAM comprising an amino acid sequence of Formula I. Related populations of cells, pharmaceutical compositions, methods of making the cells, methods of treating or preventing a condition in a subject, and methods of enhancing an antigen-specific immune response in a subject are also disclosed.
    Type: Application
    Filed: November 12, 2021
    Publication date: January 18, 2024
    Inventors: Paul E. Love, Guillaume Gaud, Christian S. Hinrichs, John S. Davies
  • Anti-human papillomavirus 16 E6 T cell receptors
    Patent number: 9822162
    Abstract: Disclosed is a T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of human papillomavirus (HPV) 16 E6, E629-38. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of a condition in a mammal and methods of treating or preventing a condition in a mammal, wherein the condition is cancer, HPV 16 infection, or HPV-positive premalignancy.
    Type: Grant
    Filed: July 14, 2014
    Date of Patent: November 21, 2017
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Christian S. Hinrichs, Steven A. Rosenberg
  • ANTI-HUMAN PAPILLOMAVIRUS 16 E7 T CELL RECEPTORS
    Publication number: 20220372103
    Abstract: Disclosed is a synthetic T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of human papillomavirus (HPV) 16 E7, E711-19. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of a condition in a mammal and methods of treating or preventing a condition in a mammal, wherein the condition is cancer, HPV 16 infection, or HPV-positive premalignancy.
    Type: Application
    Filed: August 1, 2022
    Publication date: November 24, 2022
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Christian S. Hinrichs, Steven A. Rosenberg
  • ANTI-HUMAN PAPILLOMAVIRUS 16 E6 T CELL RECEPTORS
    Publication number: 20190309043
    Abstract: Disclosed is a T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of human papillomavirus (HPV) 16 E6, E629-38. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of a condition in a mammal and methods of treating or preventing a condition in a mammal, wherein the condition is cancer, HPV 16 infection, or HPV-positive premalignancy.
    Type: Application
    Filed: May 10, 2019
    Publication date: October 10, 2019
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Christian S. Hinrichs, Steven A. Rosenberg
  • ANTI-HUMAN PAPILLOMAVIRUS 16 E7 T CELL RECEPTORS
    Publication number: 20190085047
    Abstract: Disclosed is a synthetic T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of human papillomavirus (HPV) 16 E7, E711-19. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of a condition in a mammal and methods of treating or preventing a condition in a mammal, wherein the condition is cancer, HPV 16 infection, or HPV-positive premalignancy.
    Type: Application
    Filed: November 30, 2018
    Publication date: March 21, 2019
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Service
    Inventors: Christian S. Hinrichs, Steven A. Rosenberg
  • ANTI-HUMAN PAPILLOMAVIRUS 16 E7 T CELL RECEPTORS
    Publication number: 20210130432
    Abstract: Disclosed is a synthetic T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of human papillomavirus (HPV) 16 E7, E711-19. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of a condition in a mammal and methods of treating or preventing a condition in a mammal, wherein the condition is cancer, HPV 16 infection, or HPV-positive premalignancy.
    Type: Application
    Filed: November 23, 2020
    Publication date: May 6, 2021
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Christian S. Hinrichs, Steven A. Rosenberg
  • ANTI-HUMAN PAPILLOMAVIRUS 16 E7 T CELL RECEPTORS
    Publication number: 20170145070
    Abstract: Disclosed is a synthetic T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of human papillomavirus (HPV) 16 E7, E711-19. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of a condition in a mammal and methods of treating or preventing a condition in a mammal, wherein the condition is cancer, HPV 16 infection, or HPV-positive premalignancy.
    Type: Application
    Filed: May 29, 2015
    Publication date: May 25, 2017
    Applicant: The USA, as represented by the Secretary, Department of Health and Human Services
    Inventors: Christian S. Hinrichs, Steven A. Rosenberg
  • ANTI-HUMAN PAPILLOMAVIRUS 16 E6 T CELL RECEPTORS
    Publication number: 20210130433
    Abstract: Disclosed is a T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of human papillomavirus (HPV) 16 E6, E629-38. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of a condition in a mammal and methods of treating or preventing a condition in a mammal, wherein the condition is cancer, HPV 16 infection, or HPV-positive premalignancy.
    Type: Application
    Filed: January 6, 2021
    Publication date: May 6, 2021
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Christian S. Hinrichs, Steven A. Rosenberg
  • ANTI-HUMAN PAPILLOMAVIRUS 16 E6 T CELL RECEPTORS
    Publication number: 20160152681
    Abstract: Disclosed is a T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of human papillomavirus (HPV) 16 E6, E629-38. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of a condition in a mammal and methods of treating or preventing a condition in a mammal, wherein the condition is cancer, HPV 16 infection, or HPV-positive premalignancy.
    Type: Application
    Filed: July 14, 2014
    Publication date: June 2, 2016
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Serv
    Inventors: Christian S. Hinrichs, Steven A. Rosenberg
  • ANTI-HUMAN PAPILLOMAVIRUS 16 E6 T CELL RECEPTORS
    Publication number: 20230340066
    Abstract: Disclosed is a T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of human papillomavirus (HPV) 16 E6, E629-38. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of a condition in a mammal and methods of treating or preventing a condition in a mammal, wherein the condition is cancer, HPV 16 infection, or HPV-positive premalignancy.
    Type: Application
    Filed: May 25, 2023
    Publication date: October 26, 2023
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Servic
    Inventors: Christian S. Hinrichs, Steven A. Rosenberg
Narrow Results

Filter by US Classification